Profectus BioSciences, Inc. Receives $5.6M Grant to Develop a Vaccine to Protect Humans against Infection with Nipah/Hendra Viruses

Published: May 09, 2012

BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today it has received a grant under the Partnerships for Biodefense RFA from the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH. This $5.6M award supports the preclinical development of Hendra virus soluble G (HeV-sG) as a vaccine for use in humans against either Nipah or Hendra virus infection.

Back to news